Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer’s dementia: a systematic review and network meta-analysis
Tricco AC, Ashoor HM, Soobiah C, Rios P, Veroniki AA, Hamid JS, Ivory JD, Khan PA, Yazdi F, Ghassemi M, Blondal E, Ho JM, Ng CH, Hemmelgarn B, Majumdar SR, Perrier L, Straus SE. Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer’s dementia: a systematic review and network meta-analysis. J Am Geriatr Soc. 2018 Jan;66(1):170-178. doi: 10.1111/jgs.15069.
[sidebar]
Commissioned and Funded by: Canadian Institutes of Health Research (CIHR) through the Drug Safety and Effectiveness Network (DSEN)
[/no-bottom-margin]
Share Buttons [span][/span]
[ssba-buttons] [/sidebar] [sidebar-content]- Our results can be used by patients and physicians to tailor administration of these agents
- Commissioned by the Ontario Drug Policy Research Network to inform the listing of these agents by the Ontario Public Drug Program
- Featured in >30 mass media articles
- Donepezil is likely the most effective agent for Alzheimer’s dementia across all effectiveness outcomes examined
- The agents did not increase serious adverse events but were associated with an increased risk of side effects, including nausea, vomiting, diarrhea and headache, which may result in decreased quality of life and cessation of therapy
Related Projects:
[/sidebar-content]Category : KS Projects
Date : 12 Aug 2020